News

The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.
The company and the German university hospital will initially focus on developing screening programs and precision therapies for heart diseases.
Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...
The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...
After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against ...
A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...
The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.
The study also included older children and found the best outcomes in patients between 5 years and 8 years old.
NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...
The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.
The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.
Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its ...